| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5590720 | Infection, Genetics and Evolution | 2016 | 26 Pages |
Abstract
Three integrase strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), have been approved by the FDA. Resistance against these three INSTIs have been reported and cross-resistance among them has been documented. Due to extensive and dynamic genetic diversity in different HIV-1 variants, significant differences in susceptibility to the INSTIs have been observed among HIV subtypes. This review summarizes what is known about this topic and discusses possible clinical implications.
Related Topics
Life Sciences
Agricultural and Biological Sciences
Ecology, Evolution, Behavior and Systematics
Authors
Ying-Shan Han, Thibault Mesplède, Mark A. Wainberg,